Status:
COMPLETED
Immune Response followingTdap Vaccine in Pregnancy
Lead Sponsor:
Hillel Yaffe Medical Center
Conditions:
Diphtheria-Tetanus-acellular Pertussis Vaccines
Eligibility:
FEMALE
18-45 years
Brief Summary
Pregnancy involves changes in immune response. The investigators aim to evaluate the immune response to Tdap in pregnancy in comparison to non pregnant women usig proteomics and gene sequencing.
Detailed Description
Many vaccine-preventable diseases, like influenza, pertussis, and tetanus cause substantial morbidity and mortality in pregnant women, newborns and infants. Immunization during pregnancy has the poten...
Eligibility Criteria
Inclusion
- Inclusion Criteria for pregnant women (cohort 1):
- age between 18-45 years
- pregnant women who expected to have Tdap vaccine
- Informed Consent Form signature
- Inclusion Criteria for non pregnant women (cohort 2):
- age between 18-45 years
- non pregnant women who expected to have Tdap vaccine
- Informed Consent Form signature
- Exclusion Criteria (cohort 1 and 2):
- any background immune diseases- autoimmune conditions or cancer.
- women who take immunosuppressive/ immunomodulatory medications
- a patient has received Tdap vaccine in 6 months prior to study entry.
- no will to signed the Informed Consent Form.
Exclusion
Key Trial Info
Start Date :
September 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 19 2023
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04082299
Start Date
September 12 2019
End Date
October 19 2023
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hillel Yaffe medical center
Hadera, Israel, 3810101